Skip to Content

Tigecycline Pregnancy and Breastfeeding Warnings

Tigecycline is also known as: Tygacil

Tigecycline Pregnancy Warnings

Animal studies have revealed evidence of fetal harm. Tigecycline crossed the placenta and was found in fetal tissues (including bony structures). Fetal weight reductions and increased incidence of skeletal anomalies (delayed bone ossification) were observed at exposures 5 times and equal to the daily human dose based on AUC in rats and rabbits, respectively. Increased incidence of fetal loss was found at maternotoxic doses in rabbits (exposure equal to human dose). There are no controlled data in human pregnancy. Tigecycline use during tooth development (second half of pregnancy) may cause permanent yellow-gray-brown discoloration of the teeth. FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

FDA pregnancy category: D Tigecycline should be used during pregnancy only if the benefit outweighs the risk to the fetus. Comments: -Tigecycline should not be used during tooth development unless other drugs contraindicated or unlikely to be effective. -Women who become pregnant during therapy should be advised of the potential hazard to the fetus.

See references

Tigecycline Breastfeeding Warnings

There are no data on the excretion of tigecycline into human milk. It is readily excreted into rat milk; however, due to its limited oral bioavailability, minimal or no systemic exposure occurred in pups. Caution is recommended if tigecycline is administered to a breast-feeding woman.

See references

References for pregnancy information

  1. Slover CM, Rodvold KA, Danziger LH "Tigecycline: a novel broad-spectrum antimicrobial." Ann Pharmacother 41 (2007): 965-72
  2. "Product Information. Tygacil (tigecycline)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

References for breastfeeding information

  1. "Product Information. Tygacil (tigecycline)." Wyeth-Ayerst Laboratories, Philadelphia, PA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.